← Human Trials & Peer-Reviewed Studies
Effects of angiotensin-converting enzyme inhibitor plus irbesartan on maximal and submaximal exercise capacity and neurohumoral activation in patients with congestive heart failure.
Plain-language guide to PMID 15894946 (2005): double-blind randomized controlled trial of Adrenergic beta-Antagonists.
Key Facts
- PMID
- 15894946
- Journal
- American heart journal
- Year
- 2005
- Study type
- Randomized Controlled Trial
- Authors
- Blanchet M et al. (10 authors)
- DOI
- 10.1016/j.ahj.2004.11.011
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Adrenergic beta-Antagonists, published as a randomized controlled trial.
In patients with symptomatic congestive heart failure receiving optimal therapy with an angiotensin-converting enzyme (ACE) inhibitor and a beta-blocker, the impact of using an angiotensin receptor blocker on submaximal exercise capacity and on neurohumoral activation at rest and during stress has not been investigated.
Who Took Part
The age groups tagged for this paper are middle-aged adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, double-blind and placebo-controlled study.
The participants were allocated by chance, so the Adrenergic beta-Antagonists group and the comparison group should start out alike.
Blinding on both sides kept the participants and researchers unaware of who received Adrenergic beta-Antagonists.
A placebo (an inactive look-alike) gave the Adrenergic beta-Antagonists group a baseline to be compared against.
Maximal exercise capacity was assessed using a ramp protocol.
Submaximal exercise duration was assessed using a constant load protocol, and plasma norepinephrine and angiotensin II (A-II) were measured in resting state, at 6 minutes, and at peak exercise.
What Was Measured
The subject headings attached to it are Adrenergic beta-Antagonists, Angiotensin II, Angiotensin-Converting Enzyme Inhibitors, Biphenyl Compounds, Enalapril, Exercise Tolerance and Heart Failure.
What This Means in Plain Language
The paper is a randomized, double-blind and placebo-controlled study of Adrenergic beta-Antagonists.
The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.
The publication is from 2005 (American heart journal), a journal based in United States.
More context: all human trials.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.